蛇毒蛋白C激活物的初步研究

目的：研究蝮蛇毒蛋白Ｃ激活物的分离纯化与理化性质。方法：经ＤＥ５２－纤维素、ＣＭ－Ｓｐｈａｄｅｘ Ｃ－５０、Ｇ－７５柱层析,从安徽芜湖产蝮蛇（Ａｇｋｉｓｔｒｏｄｏｎ ｈａｌｙｓ）蛇毒中纯化一种均一的蛋白Ｃ激活物（ＰＣＡ）。结果：ＳＤＳ－ＰＡＧＥ测定分子量约为１５５０００Ｄａ,ＩＥＦ－ＰＡＧＥ测定等电点为４．８。它能使人血浆的ＫＰＴＴ明显延长,显示出强烈的抗凝活性。通过中和试验与显色肽定量实验表明,     

蝮蛇毒蛋白C激活物对凝血系统的影响

目的研究蝮蛇毒纯化蛋白C激活物(PCA)的抗凝机制。方法测定PCA对正常人混浆KPTT、PT、TT的影响,对血液凝血活酶生成试验(BTGT)及PA二期法的影响以及对白兔的KPTT和Fgn的影响。结果PCA在最终浓度为0.025mg/L时对正常人混浆KPTT可明显延长,但PT和TT不受影响;当它的浓度增加到50mg/L,PT也可延长,但TT依然无明显变化;最终浓度为0.0125mg/L时,血液凝血活酶生成明显受抑制;当它的浓度增加到2.5mg/L,凝血酶生成显著减少,但抗凝血酶时间始终无明显变化;PCA可明显延长白兔的KPTT。结论PCA在低浓度时首先抑制凝血系统第一阶段内凝途径,在高浓度时也妨碍外凝途径或共同途径,BTGT和PA二期法比KPTT和PT敏感;PCA具有体内抗凝作用。     

蝮蛇毒蛋白C激活物对败血症大鼠血小板聚集性的影响

目的观察蝮蛇毒蛋白C激活物(PCA)对败血症大鼠血小板聚集性的影响。方法将健康雄性SD大鼠30只,随机分为3组,即正常对照(NC)组,内毒素(LPS)模型组和PCA预处理组,每组10只。采用大剂量腹腔注射LPS复制大鼠败血症模型,观察和对比各组大鼠的临床表现、血小板聚集性和凝血酶原时间(PT)。结果与NC组相比较LPS模型组可使血小板聚集性显著下降(P<0.01),PT明显延长(P<0.01);PCA预处理组与LPS模型组相比较血小板聚集性明显升高(P<0.01),PT较LPS模型组明显缩短(P<0.01),而与NC组比较统计学差异无显著性,同时PCA预处理组可使大鼠临床症状较LPS模型组明显减轻。结论蝮蛇毒蛋白C激活物(PCA)可明显改善败血症大鼠的血液低凝状态。     

蝮蛇毒蛋白C激活物对内毒素性离体大鼠心脏功能的影响

目的研究蝮蛇毒蛋白C激活物(PCA)组分对大鼠内毒素(LPS)性心肌损伤作用的影响。方法取SD雄性大鼠32只随机分成正常对照组、LPS组、PCA组和PCA LPS组,用Krebs-Henseleit(K-H)液对大鼠离体心脏行主动脉逆灌。在相应时点记录HR、LVSP、LVEDP、LVDP、 dp/dtmax、-dp/dtmax的变化,并测定冠脉流出液中的超氧化物歧化酶(SOD)活性、丙二醛(MDA)含量。结果PCA明显减轻LPS诱导的心功能改变并抑制心肌SOD活性降低和MDA的升高(P<0.01)。结论PCA对内毒素诱导的心肌损伤改善作用明显,其机制可能是通过保护血管内皮功能,改善微循环,稳定心肌酶活性和膜相结构等途径有关。     

蝮蛇毒蛋白C激活成份的柱层析分离及生物学性质

本文以浙江产蝮蛇毒为材料,经ＳｅｐｈａｄｅｘＧ－１００和ＤＥＡＥ－ＳｅｐｈａｄｅｘＡ５０二次柱层析,分离到的峰Ⅱ蛋白组份具有强烈抗血液凝固活性,并能够激活人血浆中的蛋白Ｃ,特异地使发色底物分解而产生颜色,生色反应光密度变化确定峰Ⅱ组份激活作用的大小。峰Ⅱ组份无直接生色作用,其激活血浆蛋白Ｃ的反应曲线类似国外同类产品Ｐｒｏｔａｃ,与激活物的蛋白浓度和血浆浓度成正比关系,但激活作用较Ｐｒｏｔａｃ弱。     

蛇毒C-型凝集素研究进展

蛇毒中含有丰富的非酶活性C－型凝集素蛋白,根据其结构及功能的差异,该类蛋白可分为Ca^2 依赖的有糖基识别活性的C－型真凝集素及无糖基识别活性的C－型凝集素样蛋白。C－型真凝集素的结构相似度高,而功能却较为单一,具有特异性糖结合活性;C－型凝集样蛋白的结构变异度大,活性亦具有多样性。后者能通过特异性的蛋白质－蛋白质相互作用而作用于血液凝固系统及血小板,从而发挥抗凝或促凝的生理功能。     

中华眼镜蛇蛇毒因子(CVF)对补体系统的作用及与人补作C_3和其他蛇毒抗原性关系

中华眼镜蛇蛇毒经DEAE-Sepharose CL-6B。HPLC等多次柱层析分离出有抗补体及溶血活性的眼镜蛇蛇毒因子(Cobra venom factor,CVF),纯化后的CVF在聚丙烯酰胺凝胶电泳图谱上呈单一区带,分子量为225000—230000,等电点为6.20。用二硫苏糖醇还原经SDS-聚丙烯酰胺凝胶电泳得三类亚基,其分子量总和为237,000。 体外抗补体及溶血试验表明,CVF的作用是通过补体旁路途经使总补体活力下降。双向免疫电泳鉴定,发现CVF与人血清作用后,其中补体成分C_3分子的抗原性发生改变,则表明CVF的作用是通过激活补体成分C_3而发挥的。给豚鼠腹腔注射CVF(0.15ug/g体重)后,其血清总补体水平下降到正常值的3％以下,7天后回升,13天后恢复到正常水平。 单相免疫电泳表明,CVF与人补体C_3抗血清间无任何交叉免疫反应,但人血清与CVF抗血清间有微弱的免疫沉淀反应。另外,CVF的氨基酸组成与人补体C_3也较为相似。鉴定还表明眼镜蛇科中四种蛇毒与CVF抗血清有强烈的免疫沉淀反应,蝰蛇毒及海蛇毒也有免疫沉淀反应,但只有眼镜蛇毒具有抗补体活性。     

眼镜蛇毒组分C的抗瘤活性及其对肿瘤细胞存活率的影响

目的观察眼镜蛇毒组分Ｃ对ＢＡＬＢ／Ｃ型小鼠腹水型肝癌Ｈ２２的抑瘤作用及其体外对肝癌Ｈ２２细胞存活率的直接影响。方法通过半体内实验,观察眼镜蛇毒组分Ｃ对小鼠腹水型肝癌Ｈ２２的抑瘤率;通过细胞培养,以细胞存活率为指标观察中华眼镜蛇毒组分Ｃ对ＢＡＬＢ／Ｃ型小鼠腹水型肝癌Ｈ２２细胞在体外的直接杀伤作用。结果眼镜蛇毒组分Ｃ能明显抑制ＢＡＬＢ／Ｃ型小鼠腹水型肝癌Ｈ２２细胞的生长,其抑瘤作用随剂量增大而增强,ＩＣ５０为９５ｍｇ／Ｌ。在体外,眼镜蛇毒组分Ｃ的浓度对ＢＡＬＢ／Ｃ型小鼠腹水型肝癌Ｈ２２细胞存活率的影响随其作用剂量的增大而增强,ＩＣ５０为９ｍｇ／Ｌ;同时,这种影响还随其作用时间的延长而增强。结论眼镜蛇毒组分Ｃ对ＢＡＬＢ／Ｃ型小鼠腹水型肝癌Ｈ２２有显著的抑瘤作用。     

人Sema4C重组腺病毒载体的构建及其在小鼠成肌细胞系C2C12中的表达

利用Ad5腺病毒载体系统构建人Sema4C基因重组腺病毒表达载体并在成肌细胞系C2C12中表达,并初步探讨Sema4C基因在成肌发育过程中的可能作用。利用脂质体介导重组腺病毒载体转染HEK293细胞,包装出完整的腺病毒;将重组腺病毒载体感染C2C12成肌细胞后,利用激光共聚焦显微镜观察发现12h即有绿色荧光表达,24h后绿色荧光蛋白表达最强;流式细胞仪检测病毒的感染效率几乎达100%。WB检测结果表明感染重组腺病毒载体组C2C12细胞Sema4C蛋白的表达量明显高于空载体对照组（P<0.01）。为了进一步观察Sema4C基因对C2C12细胞增殖分化的影响,流式细胞仪检测了病毒感染48h后C2C12细胞的增殖指数,并对感染后诱导分化的C2C12细胞的分化情况进行了观察。我们的结果首次表明,过表达外源性人Sema4C基因不仅能使C2C12细胞的G0/G1期比例增加,细胞的增殖指数下降,同时在分化培养条件下还能促进C2C12细胞肌管的形成。     

Crude honey bee venom and Bacillus thuringiensis L. Cry1c toxin in controlling wax moth Achroia grisella F. (Lepidoptera: Pyralidae)

Achroia grisella, is a noxious pest of honey bee hives. In this study the toxicity of honey bee venom and bacterial Cry1C toxin of Bacillus thuringiensis on A. grisella were assessed. In addition, the synergistic interaction between BT Cry1c and crude honey bee venom was determined. The combination of HBV and Cry1C increased the activity for both toxins. Therefore, further analysis was carried out to assess the synergistic interaction of each compound assay separately and in mixture. The results showed LC₅₀ value of 1.105 μg/μl for HBV and LC₅₀ value of 0.201 μg/μl for Cry1C. The combination bioassay result showed an LC₅₀ value of 0.549 μg/μl. The combined calculated LC₅₀ is containing lower concentration of the component toxins, this result proved that the toxicity was enhanced due to the combination. A chi square value of 39.93and relative synergistic factor ratio of 1.14 confirmed that a synergic interaction was achieved in combination.     

Phosphocalyculin C as a pyrophosphate protoxin of calyculin C in the marine sponge Discodermia calyx

Calyculin C, a minor derivative of the calyculins, has an additional methyl group on C32 of calyculin A. A recent biosynthetic study of calyculins revealed that an end product of calyculin biosynthesis is the pyrophosphate form, phosphocalyculin A. However, the pyrophosphate counterpart derived from calyculin C had not been reported. We isolated phosphocalyculin C as a minor pyrophosphate derivative, by a detailed investigation of an extract from the sponge Discodermia calyx. The treatment of phosphocalyculin C with the D. calyx cell-free extract significantly enhanced its cytotoxicity, providing molecular evidence for its role as the protoxin of calyculin C.     

C3植物中C4途径的研究进展

综述了Ｃ３植物中Ｃ４途径的发现及研究现状：阐述了Ｃ３植物中Ｃ４途径的几种作用机理;根据Ｃ３植物中Ｃ４途径的存在,探讨了改造Ｃ３植物的遗传特性;并展望了这一领域的研究前景。     

Differential susceptibility of C2C12 myoblasts and myotubes to group II phospholipase A2 myotoxins from crotalid snake venoms

Group II phospholipase A(2) (PLA(2)) myotoxins isolated from Viperidae/Crotalidae snake venoms induce a rapid cytolytic effect upon diverse cell types in vitro. Previous studies suggested that this effect could be more pronounced on skeletal muscle myotubes than on other cell types, including undifferentiated myoblasts. This study utilized the murine skeletal muscle C2C12 cell line to investigate whether differentiated myotubes are more susceptible than myoblasts, and if this characteristic is specific for the group II myotoxic PLA(2)s. The release of lactic dehydrogenase was quantified as a measure of cytolysis, 3 h after cell exposure to different group II PLA(2)s purified from Bothrops asper, Atropoides nummifer, Cerrophidion godmani, and Bothriechis schlegelii venoms. In addition, susceptibility to lysis induced by synthetic melittin and group III PLA(2) from bee (Apis mellifera) venom, as well as by anionic, cationic, and neutral detergents, was comparatively evaluated on the two cultures. Myotubes were significantly more susceptible to group II PLA(2) myotoxins, but not to the other agents tested, under the same conditions. Moreover, the increased susceptibility of myotubes over myoblasts was also demonstrated with two cytolytic synthetic peptides, derived from the C-terminal region of Lys49 PLA(2) myotoxins, that reproduce the action of their parent proteins. These results indicate that fusion and differentiation of myoblasts into myotubes induce changes that render these cells more susceptible to the toxic mechanism of group II PLA(2) myotoxins, but not to general perturbations of membrane homeostasis. Such changes are likely to involve myotoxin acceptor site(s), which remain(s) to be identified.     

Neutraligands of C5a can potentially occlude the interaction of C5a with the complement receptors C5aR1 and C5aR2

The complement system is central to the rapid immune response witnessed in vertebrates and invertebrates, which plays a crucial role in physiology and pathophysiology. Complement activation fuels the proteolytic cascade, which produces several complement fragments that interacts with a distinct set of complement receptors. Among all the complement fragments, C5a is one of the most potent anaphylatoxins, which exerts solid pro-inflammatory responses in a myriad of tissues by binding to the complement receptors such as C5aR1 (CD88, C5aR) and C5aR2 (GPR77, C5L2), which are part of the rhodopsin subfamily of G-protein coupled receptors. In terms of signaling cascade, recruitment of C5aR1 or C5aR2 by C5a triggers the association of either G-proteins or β-arrestins, providing a protective response under normal physiological conditions and a destructive response under pathophysiological conditions. As a result, both deficiency and unregulated activation of the complement lead to clinical conditions that require therapeutic intervention. Indeed, complement therapeutics targeting either the complement fragments or the complement receptors are being actively pursued by both industry and academia. In this context, the model structural complex of C5a–C5aR1 interactions, followed by a biophysical evaluation of the model complex, has been elaborated on earlier. In addition, through the drug repurposing strategy, we have shown that small molecule drugs such as raloxifene and prednisone may act as neutraligands of C5a by effectively binding to C5a and altering its biologically active molecular conformation. Very recently, structural models illustrating the intermolecular interaction of C5a with C5aR2 have also been elaborated by our group. In the current study, we provide the biophysical validation of the C5a-C5aR2 model complex by recruiting major synthetic peptide fragments of C5aR2 against C5a. In addition, the ability of the selected neutraligands to hinder the interaction of C5a with the peptide fragments derived from both C5aR1 and C5aR2 has also been explored. Overall, the computational and experimental data provided in the current study supports the idea that small molecule drugs targeting C5a can potentially neutralize C5a's ability to interact effectively with its cognate complement receptors, which can be beneficial in modulating the destructive signaling response of C5a under pathological conditions.     

脉冲电磁场对C2C12 成肌细胞增殖影响的实验研究

目的:研究不同强度脉冲电磁场干预对成肌细胞增殖的影响。方法:10Hz脉冲低频电磁场刺激经复苏后培养贴壁良好的C2C12成肌细胞,根据不同磁场强度和作用时间将其分为A、B、C组,无磁场干预的为对照组。采用RT-q PCR检测不同磁场强度下成肌细胞标记基因Myf5、Myo D及Pax7的m RNA的表达。结果:经RT-q PCR检测三种基因的表达情况,Myf5 m RNA在1.5 m T磁场强度下照射第五天表达最高;0.5 m T磁场强度下Myf5 m RNA的表达与对照组相比无统计学意义(P>0.05);1.0 m T磁场强度下Myf5 m RNA表达与对照组比较差异具有统计学意义(P<0.05);1.5 m T磁场强度下Myf5 m RNA表达与对照组比较差异具有统计学意义(P<0.05)。对照组Myo D m RNA的表达要比磁场作用下表达要高。三个磁场强度下Myo D m RNA表达与对照组相比均无统计学意义(P>0.05)。0.5 m T、1.0 m T磁场强度下Pax7 m RNA的表达要比对照组要高,与对照组相比具有统计学意义(P<0.05);1.5 m T磁场强度下Pax7 m RNA表达与对照组相比无统计学意义(P>0.05)。结论 :1.5 m T脉冲电磁场强度下作用5天对体外培养的成肌细胞Myf5 m RNA标记基因增殖促进作用最强。     

Zinc Modulates the Interaction of Protein C and Activated Protein C with Endothelial Cell Protein C Receptor

Zinc is an essential trace element for human nutrition and is critical to the structure, stability, and function of many proteins. Zinc ions were shown to enhance activation of the intrinsic pathway of coagulation but down-regulate the extrinsic pathway of coagulation. The protein C pathway plays a key role in blood coagulation and inflammation. At present there is no information on whether zinc modulates the protein C pathway. In the present study we found that Zn²⁺ enhanced the binding of protein C/activated protein C (APC) to endothelial cell protein C receptor (EPCR) on endothelial cells. Binding kinetics revealed that Zn²⁺ increased the binding affinities of protein C/APC to EPCR. Equilibrium dialysis with ⁶⁵Zn²⁺ revealed that Zn²⁺ bound to the Gla domain as well as sites outside of the Gla domain of protein C/APC. Intrinsic fluorescence measurements suggested that Zn²⁺ binding induces conformational changes in protein C/APC. Zn²⁺ binding to APC inhibited the amidolytic activity of APC, but the inhibition was reversed by Ca²⁺. Zn²⁺ increased the rate of APC generation on endothelial cells in the presence of physiological concentrations of Ca²⁺ but did not further enhance increased APC generation obtained in the presence of physiological concentrations of Mg²⁺ with Ca²⁺. Zn²⁺ had no effect on the anticoagulant activity of APC. Zn²⁺ enhanced APC-mediated activation of protease activated receptor 1 and p44/42 MAPK. Overall, our data show that Zn²⁺ binds to protein C/APC, which results in conformational changes in protein C/APC that favor their binding to EPCR.     

Generation of an antibody with a designed specificity difference for protein C and activated protein C

Rabbit polyclonal antibodies to a synthetic peptide, NH₂-Asp-Thr-Asn-Gln-Val-Asp-Gln-Lys-Asp-Gln-Leu-Asp-Phe-Arg-CONH₂ (APep), have been produced. This sequence is identical to that contained in the tetradecapeptide released from bovine protein C (PC) as a result of its conversion to its activated form (APC), except that Phe₁₃ replaced the normal Pro₁₃, in order to discourage cross-reactivity of antibodies to the carboxylterminal portion of APep with PC. The antibody pool obtained reacted with PC and showed virtually no cross-reactivity toward either APC or several typical plasma proteins. This general approach should serve well as a means of production of antibodies with a designed specificity capable of distinguishing between forms of the same protein that arise by release of peptide material.